Drugs Details

Drugs Info of Denavir
Drugs Details
  • Drugs Type  : Multum
  • Date : 14th Jan 2015 05:04 am
  • Brand Name : Denavir
  • Generic Name : penciclovir topical (Pronunciation: pen SYE kloe veer TAH pih kal)
Descriptions

DENAVIR (penciclovir) cream 1% contains penciclovir, an antiviral agent active against herpes viruses. DENAVIR is available for topical administration as a 1% white cream. Each gram of DENAVIR contains 10 mg of penciclovir and the following inactive ingredients: cetostearyl alcohol, mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water and white petrolatum. Chemically, penciclovir is known as 9-[4-hydroxy-3-(hydroxymethyl)butyl] guanine. Its molecular formula is C10H15N5O3; its molecular weight is 253.26. It is a synthetic acyclic guanine derivative and has the following structure:

Figure 1: Structural Formula of Penciclovir

DENAVIR® (penciclovir) Structural Formula Illustration

Penciclovir is a white to pale yellow solid. At 20°C it has a solubility of 0.2 mg/mL in methanol, 1.3 mg/mL in propylene glycol, and 1.7 mg/mL in water. In aqueous buffer (pH 2) the solubility is 10.0 mg/mL. Penciclovir is not hygroscopic. Its partition coefficient in n-octanol/water at pH 7.5 is 0.024 (logP = -1.62).

What are the possible side effects of penciclovir topical (Denavir)?

Serious side effects have not been reported with the use of penciclovir topical.

Other less serious side effects may be more likely to occur. Continue to use penciclovir topical and talk to your doctor if you experience:

  • headache;
  • local numbness or tingling where the cream is applied;
  • changes in taste;
  • rash; or
  • irritation at the application site.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects...

Read All Potential Side Effects and See Pictures of Denavir »

What are the precautions when taking penciclovir (Denavir)?

Before using penciclovir, tell your doctor or pharmacist if you are allergic to it; or to famciclovir; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history.

Tell your doctor if you are pregnant before using this medication. Discuss the risks and benefits with your doctor.

It is not known if this medication passes into breast milk. Consult your doctor before...

Read All Potential Precautions of Denavir »


This monograph has been modified to include the generic and brand name in many instances.

Indications

DENAVIR is a nucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age or older.

 

Dosage Administration

DENAVIR should be applied every 2 hours during waking hours for a period of 4 days. Treatment should be started as early as possible (i.e., during the prodrome or when lesions appear).

How Supplied

Dosage Forms And Strengths

Each gram of DENAVIR contains 10 mg of penciclovir in a cream base, which is equivalent to 1% (w/w).

Storage And Handling

DENAVIR is supplied in a 1.5 gram and 5 gram tube containing 10 mg of penciclovir per gram.

NDC 50816-624-01
NDC 40076-624-05

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

September 2013. Manufactured for Prestium Pharma, Inc. Newtown, PA 18940 by Novartis Pharma GmbH, Wehr, Germany Denavir® is licensed to Prestium Pharma, Inc. from Denco Asset, LLC. Revised: September 2013


This monograph has been modified to include the generic and brand name in many instances.

Side Effects

Clinical Studies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In two double-blind, placebo-controlled trials, 1516 patients were treated with DENAVIR (penciclovir cream) and 1541 with placebo. One or more local adverse reactions were reported by 3% of the patients treated with DENAVIR and 4% of placebo-treated patients. The rates of reported local adverse reactions are shown in Table 1.

Table 1 : Local Adverse Reactions Reported in Phase III Trials

  Penciclovir
n=1516
%
Placebo
N=1541
%
Application site reaction 1 2
Hypesthesia/Local anesthesia < 1 < 1
Taste perversion < 1 < 1
Rash (erythematous) < 1 < 1

Two studies, enrolling 108 healthy subjects, were conducted to evaluate the dermal tolerance of 5% penciclovir cream (a 5-fold higher concentration than the commercial formulation) compared to vehicle using repeated occluded patch testing methodology. The 5% penciclovir cream induced mild erythema in approximately one-half of the subjects exposed, an irritancy profile similar to the vehicle control in terms of severity and proportion of subjects with a response. No evidence of sensitization was observed.

Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of DENAVIR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following events have been identified from worldwide post-marketing use of DENAVIR in treatment of recurrent herpes labialis (cold sores) in adults. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to DENAVIR.

General: Headache, oral/pharyngeal edema, parosmia.

Skin: Aggravated condition, decreased therapeutic response, local edema, pain, paresthesia, pruritus, skin discoloration, and urticaria.

Read the Denavir (penciclovir) Side Effects Center for a complete guide to possible side effects

Interactions

No drug interaction studies have been performed with DENAVIR. Due to minimal systemic absorption of DENAVIR, systemic drug interactions are unlikely.


This monograph has been modified to include the generic and brand name in many instances.

Warnings

Included as part of the PRECAUTIONS section.

Precautions

General

DENAVIR should only be used on herpes labialis on the lips and face. Because no data are available, application to human mucous membranes is not recommended. Particular care should be taken to avoid application in or near the eyes since it may cause irritation. Lesions that do not improve or that worsen on therapy should be evaluated for secondary bacterial infection. The effect of DENAVIR has not been established in immunocompromised patients.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

In clinical trials, systemic drug exposure following topical administration of penciclovir cream was negligible, as the penciclovir content of all plasma and urine samples was below the limit of assay detection (0.1 mcg/mL and 10 mcg/mL, respectively). However, for the purpose of inter-species dose comparisons presented in the following sections, an assumption of 100% absorption of penciclovir from the topically applied product has been used. Based on the use of the maximal recommended topical dose of penciclovir of 0.05 mg/kg/day and an assumption of 100% absorption, the maximum theoretical plasma AUC0-24 hrs for penciclovir is approximately 0.129 mcg.hr/mL.

Carcinogenesis

Two-year carcinogenicity studies were conducted with famciclovir (the oral prodrug of penciclovir) in rats and mice. An increase in the incidence of mammary adenocarcinoma (a common tumor in female rats of the strain used) was seen in female rats receiving 600 mg/kg/day (approximately 395x the maximum theoretical human exposure to penciclovir following application of the topical product, based on area under the plasma concentration curve comparisons [24 hr. AUC]). No increases in tumor incidence were seen among male rats treated at doses up to 240 mg/kg/day (approximately 190x the maximum theoretical human AUC for penciclovir), or in male and female mice at doses up to 600 mg/kg/day (approximately 100x the maximum theoretical human AUC for penciclovir).

Mutagenesis

When tested in vitro, penciclovir did not cause an increase in gene mutation in the Ames assay using multiple strains of S. typhimurium or E. coli(at up to 20,000 mcg/plate), nor did it cause an increase in unscheduled DNA repair in mammalian HeLa S3 cells (at up to 5,000 mcg/mL). However, an increase in clastogenic responses was seen with penciclovir in the L5178Y mouse lymphoma cell assay (at doses ≥ 1000 mcg/mL) and, in human lymphocytes incubated in vitro at doses ≥ 250 mcg/mL. When tested in vivo, penciclovir caused an increase in micronuclei in mouse bone marrow following the intravenous administration of doses ≥ 500 mg/kg ( ≥ 810x the maximum human dose, based on body surface area conversion).

Impairment of Fertility

Testicular toxicity was observed in multiple animal species (rats and dogs) following repeated intravenous administration of penciclovir (160 mg/kg/day and 100 mg/kg/day, respectively, approximately 1155 and 3255x the maximum theoretical human AUC). Testicular changes seen in both species included atrophy of the seminiferous tubules and reductions in epididymal sperm counts and/or an increased incidence of sperm with abnormal morphology or reduced motility. Adverse testicular effects were related to an increasing dose or duration of exposure to penciclovir. No adverse testicular or reproductive effects (fertility and reproductive function) were observed in rats after 10 to 13 weeks dosing at 80 mg/kg/day, or testicular effects in dogs after 13 weeks dosing at 30 mg/kg/day (575 and 845x the maximum theoretical human AUC, respectively). Intravenously administered penciclovir had no effect on fertility or reproductive performance in female rats at doses of up to 80 mg/kg/day (260x the maximum human dose [BSA]). There was no evidence of any clinically significant effects on sperm count, motility or morphology in 2 placebo-controlled clinical trials of Famvir® (famciclovir [the oral prodrug of penciclovir], 250 mg b.i.d.; n=66) in immunocompetent men with recurrent genital herpes, when dosing and follow-up were maintained for 18 and 8 weeks, respectively (approximately 2 and 1 spermatogenic cycles in the human).

Use In Specific Populations

Pregnancy

Category B

There are no adequate and well-controlled studies in pregnant women.

Animal Data

No adverse effects on the course and outcome of pregnancy or on fetal development were noted in rats and rabbits following the intravenous administration of penciclovir at doses of 80 and 60 mg/kg/day, respectively (estimated human equivalent doses of 13 and 18 mg/kg/day for the rat and rabbit, respectively, based on body surface area conversion; the body surface area doses being 260 and 355x the maximum recommended dose following topical application of the penciclovir cream). Because animal reproduction studies are not always predictive of human response, penciclovir should be used during pregnancy only if clearly needed.

Nursing Mothers

There is no information on whether penciclovir is excreted in human milk after topical administration. However, following oral administration of famciclovir (the oral prodrug of penciclovir) to lactating rats, penciclovir was excreted in breast milk at concentrations higher than those seen in the plasma. Therefore, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. There are no data on the safety of penciclovir in newborns.

Pediatric Use

An open-label, uncontrolled trial with penciclovir cream 1% was conducted in 102 patients, ages 1217 years, with recurrent herpes labialis. The frequency of adverse events was generally similar to the frequency previously reported for adult patients. Safety and effectiveness in pediatric patients less than 12 years of age have not been established.

Geriatric Use

In 74 patients ≥ 65 years of age, the adverse events profile was comparable to that observed in younger patients.


This monograph has been modified to include the generic and brand name in many instances.

OverDose

Since penciclovir is poorly absorbed following oral administration, adverse reactions related to penciclovir ingestion are unlikely. There is no information on overdose.

ContrainDications

DENAVIR is contraindicated in patients with known hypersensitivity to the product or any of its components.


This monograph has been modified to include the generic and brand name in many instances.

Clinical Pharamacology

Mechanism of Action

Penciclovir is an antiviral agent active against herpes viruses [see Microbiology].

Pharmacokinetics

Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n=12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily (approximately 67 times the estimated usual clinical dose).

Pediatric Patients

The systemic absorption of penciclovir following topical administration has not been evaluated in patients < 18 years of age.

Microbiology

Mechanism of Action

The antiviral compound penciclovir has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture. However, the clinical significance of the intracellular half-life is unknown.

Antiviral Activity

In cell culture studies, penciclovir has antiviral activity against the following herpes viruses: HSV-1 and HSV-2. The antiviral activity of penciclovir against wild type strains grown on human foreskin fibroblasts was assessed with a plaque reduction assay and staining with crystal violet 3 days postinfection for HSV. The median EC50 values of penciclovir against laboratory and clinical isolates of HSV-1 and HSV-2 were 2 μM (range 1.2 to 2.4 μM, n=7) and 2.6 μM (range 1.6 to 11 μM, n=6), respectively.

Resistance

Penciclovir-resistant mutants of HSV can result from mutations in viral thymidine kinase (TK) and DNA polymerase genes. Mutations in the viral TK gene may lead to complete loss of TK activity (TK negative), reduced levels of TK activity (TK partial), or alteration in the ability of viral TK to phosphorylate the drug without an equivalent loss in the ability to phosphorylate thymidine (TK altered). The median EC50 values observed in a plaque reduction assays with penciclovir resistant HSV-1 and HSV-2 were 69 μM (range 14 to 115 μM, n=6) and 46 μM (range 4 to > 395 μM, n=9), respectively. The possibility of viral resistance to penciclovir should be considered in patients who fail to respond or experience recurrent viral shedding during therapy.

Cross-resistance

Cross-resistance has been observed among HSV DNA polymerase inhibitors. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase (TK negative) are also resistant to penciclovir.

Clinical Studies

DENAVIR was studied in two double-blind, placebo (vehicle)-controlled trials for the treatment of recurrent herpes labialis in which otherwise healthy adults were randomized to either DENAVIR or placebo. Therapy was to be initiated by the subjects within 1 hour of noticing signs or symptoms and continued for 4 days, with application of study medication every 2 hours while awake. In both studies, the mean duration of lesions was approximately one-half-day shorter in the subjects treated with DENAVIR (N=1,516) as compared to subjects treated with placebo (N=1,541) (approximately 4.5 days versus 5 days, respectively). The mean duration of lesion pain was also approximately one half-day shorter in the DENAVIR group compared to the placebo group.


This monograph has been modified to include the generic and brand name in many instances.

Patient Information

General

DENAVIR is a prescription topical cream for the treatment of cold sores (recurrent herpes labialis) that occur on the face and lips. It is not a cure for cold sores and not all patients respond to it. Do not use if you are allergic to DENAVIR (penciclovir) or any of the ingredients in DENAVIR. Before you use DENAVIR, tell your doctor if you are pregnant, planning to become pregnant, or are breast-feeding.

Instructions for Use

Wash your hands. Your face should be clean and dry. Apply a layer of DENAVIR to cover only the cold sore area or the area of tingling (or other symptoms) before the cold sore appears. Rub in the cream until it disappears. Apply the cream every 2 hours during waking hours for 4 days. Treatment should be started at the earliest sign of a cold sore (i.e. tingling, redness, itching, or bump). Wash your hands with soap and water after using DENAVIR. Store DENAVIR at room temperature between 68°F to 77°F (20°C to 25°C). Keep out of reach of children.

Possible Side Effects

DENAVIR was well tolerated in clinical studies in patients with cold sores. Common skin-related side effects that occurred when DENAVIR was applied are application site reactions, local anesthesia, and rash. Taste perversion was also reported.


This monograph has been modified to include the generic and brand name in many instances.

Consumer Overview Uses

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

 

PENCICLOVIR CREAM - TOPICAL

 

(pen-SYE-kloe-vir)

 

COMMON BRAND NAME(S): Denavir

 

USES: This medication is used to treat "cold sores/fever blisters" (herpes labialis). It can speed up healing of the sores and decrease symptoms (such as tingling, pain, burning, itching). Penciclovir belongs to a class of medications known as antivirals. It works by stopping the growth of the virus. This medication does not cure herpes, and it does not prevent passing the infection to someone else. It does not prevent future occurrences.

 

HOW TO USE: Use this medication at the first sign of infection (such as tingling, burning, redness, or sores). Wash your hands with soap and water before and after applying this medication. Clean and dry the affected areas before applying the medication. Apply a thin layer of penciclovir cream to completely cover the area of the cold sore or the area of tingling/itching/redness/swelling, and rub in gently. Apply the cream every 2 hours (except during sleep) for 4 days or as directed by your doctor.

Apply to skin only. Do not apply this medication in or near the eyes since this medication can irritate the eyes. If you do get medication in your eyes, flush with plenty of water. Do not apply inside the mouth or nose.

Dosage is based on your medical condition and response to treatment. Do not use this drug more often or for longer than prescribed.

Use this medication regularly to get the most benefit from it. This medication works best when the amount of drug absorbed by the skin stays at a constant level. Therefore, use this drug at evenly spaced intervals. To help you remember, use it at the same times each day.

Cold sores (herpes) can spread easily. Penciclovir cream does not prevent the spread of herpes. Avoid close physical contact with others (such as kissing) during an outbreak until the cold sores have completely healed. Also, try not to touch the cold sore, and wash your hands if you do touch the cold sore.

Tell your doctor if your condition persists or worsens after treatment is finished.

Consumer Overview Side Effect

SIDE EFFECTS: Redness, burning, stinging, or numbness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

 

Read the Denavir (penciclovir) Side Effects Center for a complete guide to possible side effects

Learn More »

PRECAUTIONS: Before using penciclovir, tell your doctor or pharmacist if you are allergic to it; or to famciclovir; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history.

Tell your doctor if you are pregnant before using this medication. Discuss the risks and benefits with your doctor.

It is not known if this medication passes into breast milk. Consult your doctor before breast-feeding.

Consumer Overview Missed Dose

DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.

Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

 

OVERDOSE: This medicine may be harmful if swallowed. If swallowing or overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

 

NOTES: Do not share this medication with others. Doing so may spread the infection.

Cold sore outbreaks can be triggered by many factors such as stress, hormonal changes (such as pregnancy, menstrual period), injury/surgery on the mouth (such as dental work), tiredness, sunlight, cold weather, or fever/cold/flu.

 

MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.

 

STORAGE: Store this medication at room temperature between 68-77 degrees F (20-25 degrees C). Firmly screw the cap back on the tube of medication after each use. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

 

Information last revised March 2013. Copyright(c) 2013 First Databank, Inc.

Patient Detailed Side Effect

Brand Names: Denavir

Generic Name: penciclovir topical (Pronunciation: pen SYE kloe veer TAH pih kal)

  • What is penciclovir topical (Denavir)?
  • What are the possible side effects of penciclovir topical (Denavir)?
  • What is the most important information I should know about penciclovir topical (Denavir)?
  • Who should not use penciclovir topical (Denavir)?
  • How should I use penciclovir topical (Denavir)?
  • What happens if I miss a dose (Denavir)?
  • What happens if I overdose (Denavir)?
  • What should I avoid while using penciclovir topical (Denavir)?
  • What other drugs will affect penciclovir topical (Denavir)?
  • Where can I get more information?

What is penciclovir topical (Denavir)?

Penciclovir is an antiviral medication.

Penciclovir is used topically for the treatment of recurrent cold sores.

Penciclovir topical may also be used for purposes other than those listed in this medication guide.

What are the possible side effects of penciclovir topical (Denavir)?

Serious side effects have not been reported with the use of penciclovir topical.

Other less serious side effects may be more likely to occur. Continue to use penciclovir topical and talk to your doctor if you experience:

  • headache;
  • local numbness or tingling where the cream is applied;
  • changes in taste;
  • rash; or
  • irritation at the application site.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

Read the Denavir (penciclovir) Side Effects Center for a complete guide to possible side effects

Learn More »

What is the most important information I should know about penciclovir topical (Denavir)?

Do not apply penciclovir topical to the inside of the nose or in or near the eyes, as it may cause irritation.

For best results, treatment with penciclovir topical should begin as soon as possible after symptoms appear.

Side Effects Centers
  • Denavir

Patient Detailed How Take

Who should not use penciclovir topical (Denavir)?

Penciclovir topical is in the FDA pregnancy category B. This means that it is unlikely to harm an unborn baby. Do not use penciclovir topical during pregnancy without first talking to your doctor.

It is not known whether penciclovir topical passes into breast milk. Do not use penciclovir topical if you are breast-feeding a baby without first talking to your doctor.

How should I use penciclovir topical (Denavir)?

Use penciclovir topical exactly as directed by your doctor. If you do not understand these directions, ask your doctor, nurse, or pharmacist to explain them to you.

Penciclovir topical should be applied to cold sore lesions every 2 hours while awake for a period of four days, unless otherwise directed by your doctor.

Penciclovir topical should be used to treat cold sores on the lips and face only.

For best results, treatment with penciclovir topical should begin as soon as possible after symptoms appear.

Do not apply penciclovir topical to the inside of the nose or in or near the eyes, as it may cause irritation.

Store penciclovir topical at room temperature away from moisture and heat.

Side Effects Centers
  • Denavir

Patient Detailed Avoid Taking

What happens if I miss a dose (Denavir)?

Use the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed and use only your next regularly scheduled dose.

What happens if I overdose (Denavir)?

An overdose of penciclovir topical is unlikely to threaten life. If an excessive amount of the cream has been used, or if the cream has been ingested, contact a poison control center or an emergency room for advice.

What should I avoid while using penciclovir topical (Denavir)?

There are no restrictions on food, beverages, or activity during treatment with penciclovir topical, unless otherwise directed by your doctor.

What other drugs will affect penciclovir topical (Denavir)?

Do not use other topical medications to treat the same area at them same time as penciclovir topical, unless otherwise directed by your doctor.

No other medicines have been reported to interact with penciclovir topical. Talk to your doctor or pharmacist before taking other prescription or over-the-counter medications during treatment with penciclovir topical.

Where can I get more information?

Your pharmacist has additional information about penciclovir topical written for health professionals that you may read.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 1.05. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers
  • Denavir

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI